Discover
KRRO
Korro Bio, Inc.
13.65
2 x 9.73
2 x 16.56
bid
ask
+
0.47
3.57%
2 @ 04:00 AM
13.65 +0.00 (0.00%)
| Ytd | 70.41% | |
| 1y | 4.28% |
12.79
day range
13.78
5.20
52 week range
55.89
| Open | 13.11 | Prev Close | 13.18 | Low | 12.79 | High | 13.78 | Mkt Cap | 196.87M |
| Vol | 180.37K | Avg Vol | 175.23K | EPS | -11.68 | P/E | N/A | Forward P/E | -4.29 |
| Beta | N/A | Short Ratio | 2.64 | Inst. Own | 91.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 12.14 | 200-d Avg | 16.96 | 1yr Est | 137.76 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -2.55 | -2.26 | 0.29 | 11.37% |
| 2024-08-13 | 2024-06 | -2.4 | N/A | N/A | N/A |
| 2024-08-13 | 2024-06 | -2.4 | -2.43 | -0.03 | -1.25% |
| 2024-05-14 | 2024-03 | -2.36 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -2.36 | -2.44 | -0.08 | -3.39% |
| 2024-03-29 | 2023-12 | -2.33 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-18 | Jones Trading | Upgrade | Buy | |
| 2024-11-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-21 | RBC Capital | Upgrade | Outperform | Outperform |
| 2024-10-21 | Raymond James | Upgrade | Strong Buy | |
| 2024-10-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-11-10 | AGARWAL VINEET | Chief Financial Officer | 0.00 | Conversion of Exercise of derivative security |
| 2024-04-21 | BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-04-21 | CHANG CARMEN | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-04-21 | FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-04-21 | MAKHZOUMI MOHAMAD | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-04-21 | MATHERS EDWARD T. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Atlas Venture Life Science Advisors, LLC | 1.14M | 49.23M | 12.14% |
| 2024-09-29 | NEA Management Company, LLC | 1.09M | 47.22M | 11.64% |
| 2024-09-29 | Deep Track Capital, Lp | 850.00K | 36.80M | 9.07% |
| 2024-09-29 | FMR, LLC | 579.56K | 25.09M | 6.19% |
| 2024-09-29 | Citadel Advisors Llc | 529.17K | 22.91M | 5.65% |
| 2024-09-29 | Blackrock Inc. | 449.95K | 19.48M | 4.80% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 291.30K | 12.61M | 3.11% |
| 2024-10-30 | iShares Russell 2000 ETF | 157.93K | 6.84M | 1.69% |
| 2024-10-30 | Fidelity Growth Company Fund | 137.67K | 5.96M | 1.47% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 80.91K | 3.50M | 0.86% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 62.28K | 2.70M | 0.66% |
| 2024-10-30 | iShares Russell 2000 Value ETF | 42.31K | 1.83M | 0.45% |